Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma
نویسندگان
چکیده
منابع مشابه
Lenvatinib in Advanced Hepatocellular Carcinoma.
Sorafenib has been the standard therapy for patients with unresectable hepatocellular carcinoma (HCC) since 2007, when it was shown to prolong survival, as verified in the SHARP trial [1] and a study conducted in the Asia-Pacific region [2] . Since then, other molecular-targeted agents superior to sorafenib in efficacy or safety in the first-line treatment of HCC were developed and tested in cl...
متن کاملSubgroup Analysis via Recursive Partitioning
Subgroup analysis is an integral part of comparative analysis where assessing the treatment effect on a response is of central interest. Its goal is to determine the heterogeneity of the treatment effect across subpopulations. In this paper, we adapt the idea of recursive partitioning and introduce an interaction tree (IT) procedure to conduct subgroup analysis. The IT procedure automatically f...
متن کاملPrognostic molecular markers in hepatocellular carcinoma (Review article
Hepatocellular carcinoma (HCC) is the 5th commonest malignancy worldwide and is the third most common cause of cancer-related death. The prevalence is different in the world. The ability to predict patients at higher risk of recurrence and with a poor prognosis would help to guide surgical and chemotherapeutic treatment according to individual risk. As understanding of hepatocarcinogenesi...
متن کاملSafety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
PURPOSE To determine the maximum tolerable dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of lenvatinib in patients with advanced hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN This multicenter, open-label, phase I, dose-escalation study included patients aged 20 to 80 years, refractory to standard therapy, and stratified by hepatic function measured usi...
متن کاملCancer Therapy: Clinical Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Purpose: To determine the maximum tolerable dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of lenvatinib in patients with advanced hepatocellular carcinoma (HCC). Experimental Design: This multicenter, open-label, phase I, dose-escalation study included patients aged 20 to 80 years, refractory to standard therapy, and stratified by hepatic function measured usi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ESMO Open
سال: 2021
ISSN: 2059-7029
DOI: 10.1016/j.esmoop.2021.100190